How could the expanded Alpha Tau clinical trial affect Ohio State University?
Ohio State University may see increased research scope from expanded Alpha Tau trial The FDA's approval of the Investigational Device Exemption supplement allows the REGAIN trial to expand its scope significantly. The trial, which is being led by Dr. Joshua Palmer at the OSUCCC - James, can now enroll up to 20 patients, up from the previous limit of 10. This expansion also includes opening the study to patients with IDH-mutant grade 4 tumors, adding a broader and more comprehensive clinical dataset. This increased scale and complexity of the clinical research at the participating academic centers could lead to greater operational activity and research revenue for Ohio State University.
- Effect
- Mild positive
- How direct
- Stated in the reporting
- When
- Within weeks
- The story
- No new developments lately
How it reaches Ohio State University
-
The U.S. Food and Drug Administration approved an Investigational Device Exemption supplement for Alpha Tau Medical Ltd.'s REGAIN trial. This approval expands the trial from 10 to 20 patients and includes additional study endpoints. Separately, the World Health Organization classified IDH-mutant grade 4 tumors.
The full event1independent outlet -
The approved supplement allows the REGAIN trial, which is led by Dr. Joshua Palmer at the OSUCCC - James, to enroll up to 20 patients, up from 10. The updated protocol also includes patients with IDH-mutant grade 4 tumors, creating a broader and more comprehensive clinical dataset for the university's research team. The expansion and increased complexity of the clinical program, including the addition of new patient cohorts and endpoints like progression-free survival, requires greater operational resources and research effort from the university.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- manilatimes.net Monday
-
public research university in Columbus, Ohio, United States
Everything about Ohio State University
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The FDA approved an IDE supplement expanding the REGAIN trial from 10 to 20 patients.manilatimes.net
- The updated protocol opens the study to patients with IDH-mutant grade 4 tumors.manilatimes.net
- Dr. Joshua Palmer, Radiation Oncologist at the OSUCCC - James, is the REGAIN study principal investigator.manilatimes.net
Why it matters
Academic medical centers like Ohio State University rely heavily on large, complex clinical trials to drive research output and secure funding. The expansion of a major oncology trial, particularly one focused on recurrent glioblastoma, represents a significant increase in the scope of research activity. This increased activity can translate into greater institutional revenue, grant opportunities, and enhanced reputation in the field of neuro-oncology.
Recurrent glioblastoma is a devastating disease with extremely limited treatment options, making clinical research in this area highly critical. The ability of the REGAIN trial to now include IDH-mutant grade 4 tumors, which the World Health Organization classified separately, broadens the scientific understanding of this aggressive brain tumor and increases the value of the data collected by the university.
What we don't know yet
- Will the expanded trial successfully generate data that supports market submission requirements for Alpha DaRT?
- What specific financial or operational resources will the expanded trial require from Ohio State University?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- manilatimes.netMonday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.